Key Highlights
•
The World Health Organization will propose adding steatotic liver disease (SLD) to the official global list of non-communicable diseases (NCDs) at its 2026 assembly. This is a major step to ensure this common liver condition gets the same global attention and resources as heart disease, cancer, and diabetes, which could lead to better prevention and treatment worldwide.
Source →
•
A new study has created a practical, step-by-step guide for UK hospitals to implement Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. This framework, agreed upon by doctors, dietitians, and patient groups, is crucial for making this effective obesity treatment more widely and consistently available within the constraints of the National Health Service.
Source →
•
Research in mice reveals that faulty wiring of nerves to the liver during early development can cause fatty liver disease and scarring, which in turn disrupts a key growth hormone pathway. This discovery links a neurodevelopmental disorder directly to liver health and body growth, opening new avenues for understanding and potentially treating metabolic liver conditions.
Source →
•
A new review article focuses on how to treat fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease or MASLD) in people who also have type 2 diabetes. This is important because the two conditions are closely linked, and effectively managing one can significantly improve outcomes for the other.
Source →
•
Scientists found that helpful bacteria living in our gut can train the immune system to recognize and attack cancer cells that share similar markers, making tumors more vulnerable to immunotherapy. This “antigen mimicry” between gut microbes and cancer could be harnessed to develop more effective treatments for certain patients.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
